The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000746336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
29/05/2026
Date registered
Help: Date registered
22/06/2026
Date last updated
Help: Date last updated
22/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Investigating the use of non-invasive brain stimulation to improve attention in children following acquired brain injury
Scientific title
A triple-blinded randomised sham-controlled trial evaluating home-based transcranial electrical stimulation combined with attention training in children and young people aged 8–24 years with acquired brain injury
Additional trial identifiers [1] 317420 0
None
Universal Trial Number (UTN)
Trial acronym
NIBS-Attention
Related trial records

Health condition
Health condition(s) studied:
Acquired brain injury in children 342086 0
Condition category
Condition code
Neurological 338207 338207 0 0
Other neurological disorders
Injuries and Accidents 338208 338208 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Children and young people aged 8–24 years with acquired brain injury will participate in a triple-blinded, randomised, sham-controlled trial evaluating home-based transcranial electrical stimulation (tES) delivered concurrently with attention training (NIBS-Attention).

Participants will be randomly allocated to one of three intervention arms:

• Arm 1: Active transcranial direct current stimulation (tDCS): 1 mA direct current delivered continuously for 20 minutes, including 60-second ramp-up and 60-second ramp-down periods.

• Arm 2: Active transcranial alternating current stimulation (tACS): 2 mA peak-to-peak sinusoidal stimulation (±1 mA amplitude), beta frequency stimulation (20 Hz), delivered continuously for 20 minutes, including 60-second ramp-up and 60-second ramp-down periods.

• Arm 3: Sham tACS: stimulation will mimic the initial sensation of active stimulation using a 60-second ramp-up followed by a 30-second ramp-down period, after which no active current will be delivered for the remainder of the 20-minute session.

Stimulation will be administered using a neuroConn DC-STIMULATOR PLUS device with two 5 × 5 cm saline-soaked sponge electrodes positioned bilaterally over the inferior frontal cortices according to the international 10–20 EEG system (F8 and F7). Stimulation will be delivered once daily from Monday to Friday over two consecutive weeks, for a total of 10 sessions.

During stimulation, participants will complete a computerised attention training task consisting of a gamified stop-signal paradigm ("Sorting Game"). In this task, participants are required to sort visually presented stimuli according to predefined rules while inhibiting responses when stop signals are presented. The training is designed to engage attentional control and response inhibition processes. The task is delivered on a study laptop and lasts approximately 20 minutes, corresponding to the duration of stimulation.

The first intervention session will take place in the clinic to assess tolerability, provide training on home administration procedures, and answer participant and caregiver questions. Baseline electroencephalography (EEG), behavioural measures, and neurocognitive assessments will be completed during this visit. Parents and/or carers will receive hands-on training and competency assessment in tES administration. Older adolescents may self-administer stimulation under supervision if deemed appropriate.

Sessions 2–9 will be conducted at home under real-time remote supervision via videoconferencing (Zoom). Research personnel will monitor correct device setup, electrode placement, stimulation initiation, task completion, and participant wellbeing throughout each session. Adherence will be monitored using attendance logs, Zoom supervision records, stimulation device session logs, and completion checklists maintained by research staff. Missed or interrupted sessions will be documented.

Participants will return to the clinic on Day 10 for the final stimulation session and repeat EEG and neurocognitive assessments. A follow-up visit will occur one week after completion of the intervention to assess maintenance of treatment effects.

The Day 1 clinic visit will last approximately 3 hours, the Day 10 clinic visit approximately 1.5 hours, each home session approximately 45 minutes, and the one-week follow-up visit approximately 25 minutes.

The primary outcome is response inhibition, measured using stop-signal reaction time obtained from the Stop-Signal Task. Secondary outcomes include interference inhibition measured using Flanker task congruency effects, fine motor dexterity measured using the Grooved Pegboard Test, and changes in functional brain connectivity assessed using EEG between baseline and Day 10.
Intervention code [1] 334212 0
Treatment: Devices
Intervention code [2] 334213 0
Rehabilitation
Description of the comparator or control
The comparator will be sham transcranial alternating current stimulation (tACS), delivered using the same neuroConn DC-STIMULATOR PLUS device, electrode montage, and procedures as the active stimulation conditions. Sham stimulation will consist of a 60-second fade-in period and a 30-second fade-out period based on the active tACS parameters (2 mA peak-to-peak sinusoidal stimulation at 20 Hz). Following the initial ramp periods, the device will automatically switch to a sham mode for the remainder of the 20-minute session, delivering a sinusoidal current of 50 µA peak-to-peak at 85 Hz. This current intensity is below the threshold considered to produce neuromodulatory effects and is intended to maintain participant blinding by mimicking the sensation of active stimulation without providing therapeutic stimulation.

Sham stimulation will be administered concurrently with the attention training task once daily from Monday to Friday over two consecutive weeks (10 sessions in total). The first and final sessions will be conducted in the clinic by the researcher and trained research assistants. The remaining eight sessions will be completed at home with assistance from parents/guardians under real-time remote supervision by the research team via Zoom. Parents/guardians will receive training in device setup and operation during the initial clinic visit, while older adolescents may self-administer stimulation under supervision where appropriate.
Control group
Placebo

Outcomes
Primary outcome [1] 345571 0
Stop Signal reaction time
Timepoint [1] 345571 0
At baseline; At the end of each daily NIBS-Attention session; Post-intervention after the completion of 10 days of NIBS-Attention; 1 week follow up after completion of 10 days of NIBS-Attention
Secondary outcome [1] 462209 0
Congruency effect for reaction time
Timepoint [1] 462209 0
At baseline; Post-intervention after the completion of 10 days of NIBS-Attention
Secondary outcome [2] 462210 0
Congruency effect for accuracy
Timepoint [2] 462210 0
At baseline; Post-intervention after the completion of 10 days of NIBS-Attention
Secondary outcome [3] 462214 0
Behavioural attention
Timepoint [3] 462214 0
At baseline; Post-intervention after the completion of 10 days of NIBS-attention; 1 week follow up after the completion of 10 days of NIBS-attention
Secondary outcome [4] 462223 0
Go reaction time
Timepoint [4] 462223 0
At baseline; At the end of each daily NIBS-Attention session; Post-intervention after the completion of 10 days of NIBS-Attention; 1 week follow up after completion of 10 days of NIBS-Attention
Secondary outcome [5] 462226 0
Commission errors
Timepoint [5] 462226 0
At baseline; At the end of each daily NIBS-Attention session; Post-intervention after the completion of 10 days of NIBS-Attention; 1 week follow up after completion of 10 days of NIBS-Attention
Secondary outcome [6] 462231 0
Total time (dominant hand)
Timepoint [6] 462231 0
At baseline; Post-intervention after the completion of 10 days of NIBS-Attention
Secondary outcome [7] 462232 0
Total time (non-dominant hand)
Timepoint [7] 462232 0
At baseline; Post-intervention after the completion of 10 days of NIBS-Attention
Secondary outcome [8] 462233 0
Functional connectivity
Timepoint [8] 462233 0
At baseline; Post-intervention after the completion of 10 days of NIBS-Attention

Eligibility
Key inclusion criteria
• Acquired brain injury (including mild to severe traumatic brain injury [TBI])
• English language skills sufficient to comprehend study information and complete assessments (self-report)
• At least three months post-injury for mild TBI.
• At least 1 year after injury (for moderate to severe TBI)

TBI severity
• Mild: Obtained a Glasgow Coma Scale (GCS) score ranging from 13 to 15 during the emergency department assessment (if applicable); experienced post-traumatic amnesia (PTA) for less than 24 hours
• Moderate: A loss of consciousness lasting from 30 minutes to 24 hours; a GCS score ranging from 9 to 12; a PTA period between 24 hours and 7 days
• Severe: GCS is less than 9; PTA extends beyond 7 days
Minimum age
8 Years
Maximum age
24 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Contra-indications to tDCS
o Metal implants
o Current or suspected pregnancy or current lactation
o Serious or unstable illness or medical condition
o Skull defects underneath stimulation sites
o Epilepsy or other seizure disorders
o Scalp wound/skin problem preventing placement of EEG and stimulation leads
• Acquired brain injury due to hypoxic-ischemic encephalopathy
• Profound memory impairments according to medical history
• Significant past medical or psychiatric history before injury
• Recent or planned change in neuroactive drugs (i.e., changed within 3 weeks of tES; e.g., anticonvulsants, benzodiazepines, GABA antagonists, etc.). The short-acting ADHD medication will be paused for 48 hours before the study begins.
• Existing neurological conditions, such as moderate to severe learning disabilities
• The existence of a condition or abnormality that, in the Investigator's judgment, could jeopardize the patient's safety or the integrity of the data.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be achieved through centralised allocation by an independent staff member who is not otherwise involved in participant recruitment, eligibility assessment, outcome assessment, intervention administration, or data analysis. The independent staff member will generate the randomisation sequence and configure the neurostimulation device according to the participant's allocated treatment group. The pre-programmed device will then be provided to the research personnel responsible for administering the intervention, without revealing the participant's allocation. As a result, participants, parents/caregivers, treating research personnel, outcome assessors, and investigators involved in data analysis will remain blinded to treatment assignment throughout the trial. The allocation sequence will be inaccessible to study personnel involved in participant enrolment and assessment until completion of data collection, except in the event of an emergency requiring unblinding.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will be performed by a staff member who will not be involved in any other aspect of the study, including participant recruitment, assessment, intervention delivery, or outcome analysis. The sequence generation will be done using sealed-envelop software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
SAMPLE SIZE
A target sample size of 60 was chosen based on practical factors like time, budget, and resource distribution, instead of relying on an initial power calculation. However, 20 participants per group is similar to many studies in the field. Point estimates with 95% confidence interval will be reported as these are exploratory. Effect sizes for all data will be calculated as Cohen’s D.

STATISTICAL ANALYSIS
Research question 1: What is the effect of tES on attentional inhibition?
Research question 2: What is the most effective tES technique (tDCS or tACS) to improve response inhibition?
Research question 3: Does the effect of tES on attention persist at 1 week following tES?
Research question 4: Are any improvements in attention correlated with improvements in fine motor abilities?
Research question 5: Does improved performance (as measured by stop-signal reaction time (SSRT) correlate with greater functional connectivity within the salience and executive networks (as measured using HD-EEG)?

To answer question 1, 2, and 3, a linear mixed models (LMMs) analysis to examine the effects of tES on behavioural performance across time will be performed. The between-subject factor will be Group (anodal tDCS, beta-tACS, sham), and the within-subject factor will be Time (baseline, final intervention, and one-week follow-up).
Separate models will be fitted for the primary outcome measure, (SSRT), and each of the secondary outcome measures including flanker congruency effect for reaction time, flanker congruency effect for accuracy, stop-signal commission errors, stop-signal Go reaction time, and Conner's 4 short form scores. The Flanker effect will be computed as the difference between mean reaction time and accuracy on incongruent versus congruent trials, reflecting selective attention and interference control. Commission errors will represent the proportion of responses made on No-Go trials, indexing response inhibition. We will also plot the slope of Go reaction time for the stop-signal task

Each model will include fixed effects of Group, Time, and their interaction (Group × Time) to test both the overall effectiveness of transcranial electrical stimulation and potential differential effects between stimulation techniques across time points. Participant will be entered as a random intercept to account for repeated measures within individuals. Where appropriate, random slopes for Time will be included to model individual trajectories.
Effect sizes (Cohen’s d) and 95% confidence intervals will be reported for all significant effects. Statistical significance will be set at p < .05. Analyses will be performed using R-studio or equivalent statistical software.

For research question 4, we will perform a correlation analysis for total time to complete a pegboard task score for both dominant and non-dominant hands with SSRT at each time point.

For research question 5, we will use MATLAB SPM 12 software toolbox (Wellcome Department of Imaging Neuroscience, UCL. Released 2014. Statistical Parametric Mapping 12 for Mac OS, London, UK: The MathWorks, Inc.) to investigate functional connectivity between brain regions. Participants’ connectivity measures (e.g., global and local efficiency) will be regressed against their Flanker effect for RTs.






Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29555 0
Queensland Children's Hospital - South Brisbane
Recruitment postcode(s) [1] 45878 0
4101 - South Brisbane

Funding & Sponsors
Funding source category [1] 321995 0
University
Name [1] 321995 0
Professor Karen Barlow - Start Up Funds from The University of Queensland
Country [1] 321995 0
Australia
Primary sponsor type
Individual
Name
Professor Karen Barlow, Centre for Children's Health Research, The University of Queensland
Address
Country
Australia
Secondary sponsor category [1] 324870 0
None
Name [1] 324870 0
Address [1] 324870 0
Country [1] 324870 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320529 0
Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee
Ethics committee address [1] 320529 0
Ethics committee country [1] 320529 0
Australia
Date submitted for ethics approval [1] 320529 0
20/10/2025
Approval date [1] 320529 0
06/11/2025
Ethics approval number [1] 320529 0
HREC/21/QCHQ/73034 protocol f8.0 amendment
Ethics committee name [2] 320539 0
The University of Queensland Human Research Ethics Committee A
Ethics committee address [2] 320539 0
Ethics committee country [2] 320539 0
Australia
Date submitted for ethics approval [2] 320539 0
09/11/2022
Approval date [2] 320539 0
09/11/2022
Ethics approval number [2] 320539 0
2021/HE001116

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150766 0
Prof Karen Barlow
Address 150766 0
Centre for Children's Health Research, Level 6 62 Graham St South Brisbane QLD 4101
Country 150766 0
Australia
Phone 150766 0
+61 7 3069 7486
Fax 150766 0
Email 150766 0
Contact person for public queries
Name 150767 0
Auwal Bello Hassan
Address 150767 0
Centre for Children's Health Research, Level 6 62 Graham St South Brisbane QLD 4101
Country 150767 0
Australia
Phone 150767 0
+61 405581810
Fax 150767 0
Email 150767 0
Contact person for scientific queries
Name 150768 0
Auwal Bello Hassan
Address 150768 0
Centre for Children's Health Research, Level 6 62 Graham St South Brisbane QLD 4101
Country 150768 0
Australia
Phone 150768 0
+61 405581810
Fax 150768 0
Email 150768 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers

• Research participants and policy makers

Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
• Teaching research methods or developing new statistical techniques
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol  [email protected]
Statistical analysis plan  [email protected]
Informed consent form  [email protected]
Ethical approval  [email protected]


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.